New advances in menopause symptom management.

Area of Science:

• Reproductive endocrinology
• Neuroendocrinology
• Thermoregulation

Background:

• Vasomotor symptoms (VMS) are prevalent during menopause, impacting women's health and socioeconomic well-being for extended periods.
• Menopausal hormone therapy (MHT) is effective but contraindicated for some women, particularly those with increased risks for certain cancers.
• The neurokinin B (NKB) signaling pathway is implicated in mediating VMS, with connections to the median preoptic nucleus (MnPO) and thermoregulation.

Purpose of the Study:

• To review the physiological hypothalamo-pituitary-ovary (HPO) axis and neuroendocrine changes during menopause.
• To explore the role of the NKB signaling pathway in postmenopausal VMS.
• To summarize recent clinical trial data on novel NKB-antagonist therapeutics for VMS.

Main Methods:

• Review of existing literature on the HPO axis and menopause.
• Analysis of evidence from animal and human studies on neuroendocrine changes.
• Synthesis of data from recent clinical trials on NKB antagonists.

Main Results:

• Menopause involves significant neuroendocrine shifts affecting the HPO axis.
• NKB signaling is a key pathway involved in the generation of VMS.
• Emerging NKB-antagonist therapies show promise for VMS treatment.

Conclusions:

• Understanding the neuroendocrine basis of VMS is crucial for developing targeted therapies.
• NKB pathway antagonism represents a promising new therapeutic strategy for managing menopausal VMS.
• Further research and clinical trials are essential to establish the efficacy and safety of these novel agents.